✦ LIBER ✦

Therapy of childhood acute myelogenous leukemias

✍ Scribed by J. Vormoor; J. Boos; K. Stahnke; H. Jürgens; J. Ritter; U. Creutzig

Book ID: 105990158
Publisher: Springer
Year: 1996
Tongue: English
Weight: 234 KB
Volume: 73
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s002770050193

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Therapy of acute myelogenous leukemia

✍ Emil J. Freireich; Michael J. Keating; Edmund A. Gehan; Kenneth B. McCredie; Ger 📂 Article 📅 1978 🏛 John Wiley and Sons 🌐 English ⚖ 726 KB

Incidence of secondary acute myelogenous

Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia

✍ Susan G. Kreissman; Richard D. Gelber; Harvey J. Cohen; Luis A. Clavell; Pearl L 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 580 KB

A homoharringtonine-based regimen for ch

A homoharringtonine-based regimen for childhood acute myelogenous leukemia

✍ Tang, JingYan ;Xue, Huiliang ;Pan, Ci ;Chen, Jing ;Gu, LongJun ;Zhao, HuiJun 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

Therapy-related acute myelogenous leukem

✍ Gautam Borthakur; Elihu E. Estey 📂 Article 📅 2007 🏛 Current Science Inc. 🌐 English ⚖ 216 KB

Differentiation therapy in acute myeloge

Differentiation therapy in acute myelogenous leukemia (non-APL)

✍ Waxman, S 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 137 KB

Antibody therapy for residual disease in

Antibody therapy for residual disease in acute myelogenous leukemia

✍ Joseph G. Jurcic 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 163 KB

The elimination of minimal residual disease remains one of the most promising applications of monoclonal antibody (mAb)-based therapies. An early study showed that treatment with iodine-131 (131I)-labeled anti-CD33 mAb M195 had antileukemic effects when given as postremission therapy to patients wit